Project Grant R01CA284172
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$705K
Federal Agency
National Cancer Institute
Federal Grant Program
93.394
Assistance Type
Project Grant
Place of Performance
Irwindale, CA 91010, USA
Similar Awards
This $538,553 Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) will fund a longitudinal study to investigate the use of quantitative multiparametric MRI (mpMRI) features and circulating tumor cells (CTCs) as early markers of patient outcomes after radiation therapy (RT) and androgen deprivation therapy (ADT) in prostate cancer patients. The University of Miami will lead this research, which aims to develop a multivariable model that...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $598,046 to Case Western Reserve University (CWRU) to develop a rapid and reproducible magnetic resonance fingerprinting (MRF) method. The goal is to quantitatively and accurately characterize prostatic peripheral zone tissue to limit overdiagnosis and overtreatment of prostate cancer patients without clinically significant disease. The key products...
This $256,000 National Science Foundation Project Grant under the Engineering (47.041) program will support the development of an artificial intelligence-based system for analyzing multiparametric magnetic resonance imaging (MRI) scans to detect prostate lesions. The awardee, Taurus Diagnostics, Inc., will create a novel prostate cancer diagnostic platform leveraging artificial intelligence image analysis for high sensitivity and specificity. Key objectives include developing methods to...
This $568,151 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop a real-time photoacoustic imaging platform to accurately detect and characterize the aggressiveness of prostate cancer tumors. The Regents of the University of Michigan, the awardee, will optimize photoacoustic nanoprobes to enable chemical imaging of the tumor microenvironment, target prostate cancer, and assess prostate gland...
This Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is funding research to develop advanced AI-assisted prostate MRI interpretation capabilities. The $245,087 award to the University of Delaware will be used to: Curate a comprehensive dataset of 300 public and 50 Memorial Sloan Kettering (MSK) prostate MRI scans with corresponding PIRADS radiology reports. The University of Delaware team will leverage natural...
This $989,122 Project Grant award from the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to evaluate the accuracy and performance of four commercial mammography-based artificial intelligence (AI) algorithms for breast cancer risk prediction. The project will use a large, diverse screening population from the Breast Cancer Surveillance Consortium to assess the ability of these AI models to improve clinical risk prediction and reduce...
This Project Grant award from the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $680,433 to The Regents of the University of California, San Francisco (UCSF) for a 5-year research project. The project aims to apply advanced spatial proteogenomic technologies and pathology artificial intelligence (PAI) analysis to better understand prostate cancer heterogeneity, identify novel prognostic markers, and illuminate the...
This Project Grant award of $692,248, funded by the National Cancer Institute (NCI) under the Cancer Detection and Diagnosis Research program (CFDA 93.394), aims to develop novel analytic methods for disease ruling in cancer diagnosis. The project, awarded to Emory University, will focus on establishing an analytic paradigm and statistical/computational methods for simultaneously ruling out and ruling in aggressive cancer, particularly in the context of prostate cancer diagnosis. Key...
The National Cancer Institute awarded a $632,300 Project Grant (CFDA 93.396 - Cancer Biology Research) to Carnegie Mellon University to develop an integrated ultrahigh-throughput 3D volumetric super-resolution imaging system for cancer research. The award period is from April 1, 2025 to March 31, 2030. The proposed system will combine a multiscale fluorescence mesoscope with magnify expansion microscopy to enable rapid, large-area 3D imaging of the tumor microenvironment at subcellular...
The National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $1,963,241.55 Cooperative Agreement to Dignity Health (doing business as St. Joseph's Hospital and Medical Center) to optimize and validate quantitative magnetic resonance imaging (MRI) methods for early prediction of brain cancer response to therapy. The key products and services to be delivered include: Implementing multi-vendor spin and gradient echo (SAGE) dynamic...